A biotechnology firm has reached a key milestone in its partnership with a major pharmaceutical company, designating a novel target for obesity treatment discovered by studying the biology of hibernating mammals.
The target was identified using Fauna Bio's proprietary Convergence AI platform, which analyzes genomic data from over 450 mammal species, including more than 60 that hibernate. The platform integrates this comparative biology with human patient data to pinpoint potential therapeutic approaches. The designated target represents a potential first-in-class strategy inspired by how hibernators naturally and healthily regulate their body weight and metabolism throughout seasonal cycles.
"By studying how hibernating mammals achieve remarkable feats of metabolic regulation, including dramatic, healthy weight cycling, we are uncovering therapeutic targets that have eluded traditional discovery approaches," said Ashley Zehnder, CEO of Fauna Bio. The company's platform uses a proprietary Graph Neural Network to evaluate and prioritize such novel targets rapidly. This milestone triggers a payment to Fauna Bio under the terms of its strategic collaboration with Eli Lilly and Company, which began in late 2023.
The approach signifies a shift towards leveraging extreme animal physiology for human medicine. Instead of focusing solely on human pathology, researchers are looking to species that have evolved natural resistances to conditions like obesity and metabolic disease. The goal is to translate these biological insights into innovative therapies that could offer new mechanisms of action for weight management.
With the target now designated, the collaboration moves into its next phase, which will involve further validation and the beginning of therapeutic development work. The advancement offers a hopeful outlook for the discovery of new obesity treatments, highlighting the growing role of non-traditional biological data and artificial intelligence in pioneering future medicines.